* Crinetics Pharmaceuticals Inc CRNX.OQ reported a
quarterly
adjusted loss of 94 cents per share for the quarter ended in
June, identical to the same quarter last year. The mean
expectation of thirteen analysts for the quarter was for a loss
of 86 cents per share. Wall Street expected results to range
from $-1.06 to -69 cents per share.
* Revenue fell 59.6% to $399.00 thousand from a year ago;
analysts
expected $510.00 thousand.
* Crinetics Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 94 cents.
* The company reported a quarterly loss of $74.06 million.
* Crinetics Pharmaceuticals Inc shares had risen by 7.8%
this
quarter and gained 35.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 4% in
the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Crinetics
Pharmaceuticals Inc is $70.00
This summary was machine generated from LSEG data August 8 at
10:49 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.86 -0.94 Missed
Mar. 31 2024 -0.81 -0.93 Missed
Dec. 31 2023 -0.86 -0.90 Missed
Sep. 30 2023 -0.86 -1.01 Missed